Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)

Chronic Myeloid Leukemia (CML) With Philadelphia Chromosome-positive (Ph+) Clinical Trial

Official title: Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the hematological, cytogenetic and molecular response to continuous-use of Imatinib in children with CML Ph+.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Abnormal Karyotype
• Chronic Myeloid Leukemia (CML) With Philadelphia Chromosome-positive (Ph+)
• Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Philadelphia Chromosome

• NCT number: NCT01221376
• Study type: Interventional
• Source: Hospital Santa Marcelina
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: February 2011
• Completion date: December 2013